OS Therapies Inc OSTX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

("OS Therapies," the "Company," "we," "our" or "us") is a clinical stage biopharmaceutical

company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our

mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is an

extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing genotypes and

Last close 1.25 2026-10-23
Market cap $57.7M 2026-06-30 share count
52-week range 1.15 - 2.25

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.98

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
R&D $16.4M$2.8M$3.2M—
SG&A $12.3M$4.0M$1.1M—
Operating income -$28.7M-$6.8M-$4.3M—
Interest expense —$2.1M$3.4M—
Net income -$28.8M-$8.9M-$7.8M—
EPS, basic -0.98-1.28-1.46—
EPS, diluted -0.98-1.28-1.46—
Shares, diluted (wtd. avg.) 29.3M7.0M5.4M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $269.8K$5.5M$39.0K$171.5K
Total current assets $332.9K$5.5M$790.0K—
Property, plant and equipment $2.5K$5.3K$8.1K—
Other intangibles $6.5M———
Total assets $6.8M$5.5M$798.1K—
Accounts payable $9.9M$1.7M$2.7M—
Short-term debt ——$100.0K—
Total current liabilities $11.8M$4.6M$24.7M—
Total liabilities $11.9M$4.7M$24.8M—
Retained earnings -$67.2M-$38.4M-$29.5M—
Total equity -$6.1M-$3.3M-$24.0M-$17.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$14.2M-$7.3M-$3.0M—
Depreciation and amortisation —$2.8K$4.2K—
Stock-based compensation $4.3M$268.3K——
Capital expenditure $466.4K———
Investing cash flow -$466.4K—$1.1K—
Financing cash flow $9.4M$12.8M$2.9M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036629.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 Net income, FY2023: -7.8M Net income, FY2024: -8.9M Net income, FY2025: -28.8M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — — — —
Gross profit — — — —
Net income — -$7.8M -$8.9M -$28.8M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement signed Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Unregistered share sale Item 3.02
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Unregistered share sale Item 3.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%